tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Polyomavirus Infections D027601 1 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Hernia, Ventral D006555 1 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Apraxias D001072 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Nocturia D053158 1 associated lipids
Echinostomiasis D004451 1 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Rectal Diseases D012002 1 associated lipids
Citrullinemia D020159 1 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Sweet Syndrome D016463 1 associated lipids
Optic Neuritis D009902 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Meiser BM and Reichart B New trends in clinical immunosuppression. 1994 Transplant. Proc. pmid:7527954
Braun F et al. Primary tacrolimus immunosuppression in kidney recipients considered "higher immunological risk". 2000 Transplant. Proc. pmid:11119893
Nakajima K et al. Effects of triple therapy of cyclosporine, FK 506, and RS-61443 on allogeneic small bowel transplantation in dogs. 1993 Transplant. Proc. pmid:7679821
Ohtsuka S et al. Hamster-to-rat xenotransplantation of whole pancreas by FK 506 combined with splenectomy. 1994 Transplant. Proc. pmid:7513473
Hu RH et al. Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients. 2000 Transplant. Proc. pmid:11119894
Kamińska D et al. Significant infections after hand transplantation in a Polish population. 2014 Transplant. Proc. pmid:25380943
Goto T et al. FK 506: historical perspectives. 1991 Transplant. Proc. pmid:1721254
Ciancio G et al. Current advantage of FK 506 in cadaveric kidney transplantation. 1996 Transplant. Proc. pmid:8623207
Jain AB et al. FK 506 dosage in human organ transplantation. 1990 Transplant. Proc. pmid:1689890
Bilbao I et al. Indications and management of everolimus after liver transplantation. 2009 Jul-Aug Transplant. Proc. pmid:19715864
TuÄŸcu M et al. Tacrolimus-Induced Diabetic Ketoacidosis and Effect of Switching to Everolimus: A Case Report. 2015 Transplant. Proc. pmid:26093759
Marin-Gomez LM et al. Evaluation of clinical safety of conversion to Advagraf therapy in liver transplant recipients: observational study. 2009 Jul-Aug Transplant. Proc. pmid:19715867
Aktürk S et al. Pregnancy After Kidney Transplantation: Outcomes, Tacrolimus Doses, and Trough Levels. 2015 Transplant. Proc. pmid:26093738
García-Meseguer C et al. Efficacy and safety of basiliximab in pediatric renal transplantation. 2002 Transplant. Proc. pmid:11959206
Shoji T et al. Long-term acceptance of porcine pulmonary allografts without chronic rejection. 2005 Jan-Feb Transplant. Proc. pmid:15808551
Charco R et al. A prospective, multicenter study of once-daily extended-release tacrolimus in de novo liver transplant recipients. 2011 Transplant. Proc. pmid:21486582
Ortiz de Urbina J et al. Advagraf de novo in liver transplantation: a single-center experience. 2011 Transplant. Proc. pmid:21486583
Wiesner RH Long-term comparison of tacrolimus versus cyclosporine in liver transplantation. The US FK Study Group. 1998 Transplant. Proc. pmid:9636565
Van Buren D et al. Renal function in primary liver transplant recipients receiving neoral (cyclosporine) versus prograf (tacrolimus). 1998 Transplant. Proc. pmid:9636566
Qu W et al. Correlation Between Immunosuppressive Therapy and CD4(+) T-Cell Intracellular Adenosine Triphosphate Levels in Liver Transplant Recipients. Transplant. Proc. pmid:27569951
Hossain MA et al. Effect of the immunosuppressants FK506 and D-allose on allogenic orthotopic liver transplantation in rats. 2000 Transplant. Proc. pmid:11120048
Mañez R et al. Association between donor-recipient HLA-DR compatibility and cytomegalovirus hepatitis and chronic rejection in liver transplantation. 1993 Transplant. Proc. pmid:7680170
Kliem V et al. Conversion to tacrolimus for acute corticosteroid- and antibody-resistant rejection following kidney transplantation. 1999 Transplant. Proc. pmid:10576041
Müller MK et al. Inhibition of insulin release by FK 506 and its prevention by rioprostil, a stable prostaglandin E1 analogue. 1991 Transplant. Proc. pmid:1721286
Ketel BL et al. Tacrolimus-based vs cyclosporine-based immunotherapy in combined kidney-pancreas transplantation. 1996 Transplant. Proc. pmid:8623453
Gonzalez-Molina M et al. Mycophenolate mofetil and tacrolimus reduce mortality after deceased donor kidney transplantation. 2012 Transplant. Proc. pmid:23146459
Batista F et al. Long-term follow-up after conversion from tacrolimus to cyclosporin in renal transplant patients with new-onset diabetes mellitus after transplantation. 2012 Transplant. Proc. pmid:23146461
Yasunami Y et al. Characterization of the immunosuppressive activity of FK 506 in rat islet allografts. 1990 Transplant. Proc. pmid:1691557
Yeung S et al. Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. 2004 Transplant. Proc. pmid:15518754
Kawaoka T et al. Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report. 2015 Transplant. Proc. pmid:25891736
Bruce DS et al. Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation. 1998 Transplant. Proc. pmid:9636625
Deardon DJ et al. Small bowel tonometry: a possible technique for detecting early small bowel allograft dysfunction. 1993 Transplant. Proc. pmid:7505502
Hayashi S et al. Synergistic effect of donor pretreatment using FK 506 in hamster-to-rat cardiac xenotransplantation. 1994 Transplant. Proc. pmid:7518126
Curro G et al. Transient ischemic attack after rizatriptan administration in a liver transplant recipient: a case report. 2006 Transplant. Proc. pmid:17112920
Ohtsuka S et al. Mechanism of antibody production in guinea pig to rat discordant xenotransplant: establishment of a simple model by intravenous injection of discordant splenocytes. 1994 Transplant. Proc. pmid:7518130
Uchida H et al. Experimental intestinal transplantation using mouse fetal intestine in the rat: combination effect of FK 506 with cyclophosphamide. 1999 Transplant. Proc. pmid:10578297
Woodle ES et al. Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection. 1993 Transplant. Proc. pmid:7682358
Senninger N et al. Glucose metabolism following liver transplantation and immunosuppression with cyclosporine A or FK 506. 1995 Transplant. Proc. pmid:7533364
Woodle ES et al. FK 506 rescue therapy: early conversion improves efficacy. 1993 Transplant. Proc. pmid:7682359
Loss M et al. Influence of long-term cyclosporine or FK 506 therapy on glucose and lipid metabolism in stable liver graft recipients. 1995 Transplant. Proc. pmid:7533365
Yagihashi A et al. The effect of FK 506 on peripheral blood T-lymphocyte subsets in orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721318
Woo J et al. Effects of FK 506, mycophenolic acid, and bredinin on OKT-3-, PMA-, and alloantigen-induced activation molecule expression on cultured CD4+ and CD8+ human lymphocytes. 1991 Transplant. Proc. pmid:1721319
Wasilewski G et al. Inadequate blood pressure control in orthotopic heart transplant: is there a role of kidney function and immunosuppressive regimen? 2014 Transplant. Proc. pmid:25380929
Jin KB et al. The production of reactive oxygen species in tacrolimus-treated glial cells. 2008 Transplant. Proc. pmid:18929834
Tanabe K et al. Synergistic effect of high-dose mizoribine and low-dose tacrolimus on renal allograft survival in nonhuman primates. 2002 Transplant. Proc. pmid:12176425
Chung YW et al. Transcriptional activation of nuclear-related factor 2 by FK506 in Jurkat T cells. 2015 Transplant. Proc. pmid:25891728
Benedini S et al. Glucose and leucine metabolism in lung tranplanted patients on low dose of steroids for immunosuppressive therapy. 2008 Transplant. Proc. pmid:18589153
Tashiro H et al. Monitoring for engraftment of rat orthotopic liver transplantation by semiquantitative PCR. 1995 Transplant. Proc. pmid:7533421
Numakura K et al. Incidence and risk factors of clinical characteristics, tacrolimus pharmacokinetics, and related genomic polymorphisms for posttransplant diabetes mellitus in the early stage of renal transplant recipients. 2005 Transplant. Proc. pmid:15919487
Felser I et al. Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721350
Krämer BK et al. Cardiovascular risk estimates and risk factors in renal transplant recipients. 2005 Transplant. Proc. pmid:15919488
Wlodarczyk Z et al. Lipid metabolism in renal transplant patients receiving tacrolimus/sirolimus combination therapy. 2005 Transplant. Proc. pmid:15919489
Moro JA et al. Randomized prospective study of the evolution of renal function depending on the anticalcineurin used. 2008 Transplant. Proc. pmid:19010143
Fukuhara N et al. Long-term outcome of tacrolimus in cadaveric kidney transplantation from non-heart-beating donors. 2002 Transplant. Proc. pmid:12176492
Barrera-Pulido L et al. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients. 2008 Transplant. Proc. pmid:19010156
Tanabe K et al. Outcome of kidney transplantation from non-heart-beating donors followed by tacrolimus immunosuppression in japan. 2002 Transplant. Proc. pmid:12176493
Gruttadauria S et al. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation. 2005 Jul-Aug Transplant. Proc. pmid:16182762
Takahashi N et al. Nitric oxide generation in renal allograft recipients. 1998 Transplant. Proc. pmid:9838306
Yoshimura N et al. Effect of local immunosuppressive therapy with FK 506 on renal allograft survival in the mongrel dog. 1998 Transplant. Proc. pmid:9838372
Gojowy D et al. High Frequency of Arterial Hypertension in Patients After Liver Transplantation. 2016 Transplant. Proc. pmid:27496479
Ramirez CB et al. Early steroid withdrawal after liver transplantation. 1998 Transplant. Proc. pmid:9838406
Wilusz M et al. Effects of Immunosuppressive Drugs on Serum Fatty Acids of Phospholipids Fraction in Renal Transplant Recipients. 2016 Transplant. Proc. pmid:27496457
Sellers M et al. Incidence of late acute rejection and progression to chronic rejection in pediatric liver recipients. 1997 Feb-Mar Transplant. Proc. pmid:9123065
Bonatti H et al. Liver transplantation for acute liver failure in children under 1 year of age. 1997 Feb-Mar Transplant. Proc. pmid:9123068
Costa A et al. Stimulatory effect of FK506 and erythromycin on pig intestinal motility. 1996 Transplant. Proc. pmid:8907957
Cicalese L et al. Effect of FK506 on the mucosal perfusion of the rat intestinal allograft. 1996 Transplant. Proc. pmid:8907959
Sato K et al. Effectiveness of triple regimen immunosuppression in canine pancreatic allotransplantation. 1994 Transplant. Proc. pmid:7520628
Oishi M et al. Successful swine small bowel transplantation using FK506: effect on endotoxin translocation. 1994 Transplant. Proc. pmid:7520629
Miki T et al. Xenogeneic humoral graft-Vs-host disease following hamster-to-Rat bone marrow transplantation. 2000 Transplant. Proc. pmid:10936339
Moutabarrik A et al. FK 506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. 1991 Transplant. Proc. pmid:1721382
Chien YS et al. Incidence and risk factors of new-onset diabetes mellitus after renal transplantation. 2008 Transplant. Proc. pmid:18790250
Moons P et al. Steroids may compromise quality of life of renal transplant recipients on a tacrolimus-based regimen. 2002 Transplant. Proc. pmid:12176538
Navia MA Rational design of new immunosuppressive drugs. 1999 Feb-Mar Transplant. Proc. pmid:10083489
Gu B et al. Exploration of Fecal Microbiota Transplantation in the Treatment of Refractory Diarrhea After Renal Transplantation. 2018 Transplant. Proc. pmid:29880353
Gruessner AC et al. Solitary pancreas transplants: improving results and factors that influence outcome. 1997 Feb-Mar Transplant. Proc. pmid:9123468
Fishbein T et al. Isolated intestinal transplantation in adults with nonreconstructible GI tracts. 2000 Transplant. Proc. pmid:10995925
Alessiani M et al. Correlations between functional changes and different grades of acute rejection in swine small bowel allografts. 2000 Transplant. Proc. pmid:10995933
Ohtsuka S et al. The effect of short-term FK 506 therapy on pancreas transplantation in rats. 1991 Transplant. Proc. pmid:1721413
Tanabe K et al. Diabetes mellitus after renal transplantation under FK 506 (tacrolimus) as primary immunosuppression. 1996 Transplant. Proc. pmid:8658670
van Gelder T et al. ATP-binding cassette transporters and calcineurin inhibitors: potential clinical implications. 2001 Transplant. Proc. pmid:11377580
Weir MR Optimizing early de novo immunosuppression with sirolimus. 2008 Transplant. Proc. pmid:19100903
Chang HR et al. Sirolimus addition is beneficial for renal allograft dysfunction due to simultaneous acute rejection episode and calcineurin inhibitor nephrotoxicity. 2004 Transplant. Proc. pmid:15621119
Khwaja K et al. Pancreas transplantation in cross-match-positive recipients using cyclosporine- or tacrolimus-based immunosuppression. 2002 Transplant. Proc. pmid:12176621
Wang W et al. Effect of rapamycin and FK506 on mesangial cell proliferation. 2001 Feb-Mar Transplant. Proc. pmid:11267180
Curtis JJ Posttransplant hypertension. 1998 Transplant. Proc. pmid:9723370
Fukuoka N et al. Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation. 2010 Transplant. Proc. pmid:20832577
Lin CY et al. Effects of FK 506 on the biochemical markers in canine lung allograft rejection. 1991 Transplant. Proc. pmid:1721445
Jost U et al. FK 506 treatment of intractable rejection after liver transplantation. 1993 Transplant. Proc. pmid:7689276
Ito Y et al. Complete replacement of tracheal epithelia by the host promotes spontaneous acceptance of orthotopic tracheal allografts in rats. 2004 Transplant. Proc. pmid:15561264
Kiji T et al. Relationship between immunological rejection and matrix GLA protein in cryopreserved vascular allografts. 2004 Transplant. Proc. pmid:15561265
Langrehr JM et al. A prospective, randomized trial with quadruple versus dual tacrolimus-based induction after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267404
Toki K et al. Histopathologic findings in routine biopsies of renal transplant allografts. 1999 Transplant. Proc. pmid:10500759
Nakai T et al. Immunologic changes in heterotopic and orthotopic small bowel transplantation in rats. 1999 Transplant. Proc. pmid:10500761
Silber RE et al. Comparison of the effect of FK 506 and alpha/beta-T-cell antibody R73 on transplant vascular sclerosis after heterotopic rat heart transplantation. 1998 Transplant. Proc. pmid:9636398
Krüger B et al. Different effects of cyclosporine or tacrolimus on hepatocyte acute phase proteins. 1998 Transplant. Proc. pmid:9636399
Ben-Ari Z et al. Conversion of liver allograft recipients from cyclosporine A to FK 506 immunosuppressive therapy. 2000 Transplant. Proc. pmid:10856553
Wojciechowski D et al. Mycophenolate Mofetil Withdrawal With Conversion to Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients. 2017 Transplant. Proc. pmid:28923623
Nanmoku K et al. Effective and Safe Reduction of Conventional Immunosuppressants Using Everolimus in Maintenance Kidney Transplant Recipients. 2017 Transplant. Proc. pmid:28923615
Keshavamurthy M et al. Single-center study utilizing C(2) level as monitoring tool in de novo renal transplant recipients treated with Neoral. 2001 Nov-Dec Transplant. Proc. pmid:11750338
Fernando ON et al. Elective conversion of patients from cyclosporine to tacrolimus for hypertrichosis. 1998 Transplant. Proc. pmid:9636505